Gestión de la información en Educación Superior. Una experiencia de evolución del software con sistemas gestores de contenidos

La Educación Superior ofrece un vasto dominio para el diseño y desarrollo de soluciones tecnologías orientadas a la gestión de la información. Se presenta una experiencia fundadas en conceptos teóricos de la evolución del software, en particular su mantenimiento, actividad que permite modificar el mismo conservando su integridad. Esta actividad continúa durante su tiempo de vida, dado que en la práctica sufren cambios para su permanencia y utilidad; existiendo diferentes factores que inciden en su ejecución, lo que  permiten clasificarlos en mantenimiento correctivo y perfectivo, entre otros. Los Sistemas Gestores de  Contenidos o CMS son ampliamente aplicados en una  diversidad de soluciones para mediar la comunicación con los usuarios finales. En la propuesta se resume una práctica atinente a la evolución del software centrada en el mantenimiento perfectivo aplicado en un sistema gestor de contenidos de código abierto.Artículo revisado por pare

Una propuesta integradora de Mantenimiento Correctivo aplicada al Diseño Web Adaptativo y Accesibilidad Web

The increase of ICT has promoted free software such as Content Management System (CMS) that facilitate the efficient generation of digital content. CMS should be evaluated before to be to use, in order to generate accessible product. The work presents a corrective maintenance application implemented through Web Accessibility and Adaptive Web Design. The incorporation of this guidelines in software development, guarantee the quality of this products and promotes digital inclusion of individuals regardless of their abilities. El incremento de las TIC ha promovido el desarrollo de herramientas informáticas libres y gratuitas, como los Content Management System o Sistemas de Gestión de Contenidos que facilitan la generación eficaz de contenidos digitales. Éstos deben ser evaluados previos a su utilización, a los efectos de producir un producto accesible por todos los usuarios. Se presenta una experiencia de Mantenimiento Correctivo del software aplicada a la Accesibilidad Web y el Diseño Web Adaptativo. La incorporación de estas pautas en el desarrollo de software, permiten impulsar la generación de productos tecnológicos de calidad y fomentan la inclusión digital de los individuos independientemente de sus capacidade

Una propuesta integradora de Mantenimiento Correctivo aplicada al Diseño Web Adaptativo y Accesibilidad Web

The increase of ICT has promoted free software such as Content Management System (CMS) that facilitate the efficient generation of digital content. CMS should be evaluated before to be to use, in order to generate accessible product. The work presents a corrective maintenance application implemented through Web Accessibility and Adaptive Web Design. The incorporation of this guidelines in software development, guarantee the quality of this products and promotes digital inclusion of individuals regardless of their abilities. El incremento de las TIC ha promovido el desarrollo de herramientas informáticas libres y gratuitas, como los Content Management System o Sistemas de Gestión de Contenidos que facilitan la generación eficaz de contenidos digitales. Éstos deben ser evaluados previos a su utilización, a los efectos de producir un producto accesible por todos los usuarios. Se presenta una experiencia de Mantenimiento Correctivo del software aplicada a la Accesibilidad Web y el Diseño Web Adaptativo. La incorporación de estas pautas en el desarrollo de software, permiten impulsar la generación de productos tecnológicos de calidad y fomentan la inclusión digital de los individuos independientemente de sus capacidade

Una propuesta integradora de Mantenimiento Correctivo aplicada al Diseño Web Adaptativo y Accesibilidad Web

The increase of ICT has promoted free software such as Content Management System (CMS) that facilitate the efficient generation of digital content. CMS should be evaluated before to be to use, in order to generate accessible product. The work presents a corrective maintenance application implemented through Web Accessibility and Adaptive Web Design. The incorporation of this guidelines in software development, guarantee the quality of this products and promotes digital inclusion of individuals regardless of their abilities. El incremento de las TIC ha promovido el desarrollo de herramientas informáticas libres y gratuitas, como los Content Management System o Sistemas de Gestión de Contenidos que facilitan la generación eficaz de contenidos digitales. Éstos deben ser evaluados previos a su utilización, a los efectos de producir un producto accesible por todos los usuarios. Se presenta una experiencia de Mantenimiento Correctivo del software aplicada a la Accesibilidad Web y el Diseño Web Adaptativo. La incorporación de estas pautas en el desarrollo de software, permiten impulsar la generación de productos tecnológicos de calidad y fomentan la inclusión digital de los individuos independientemente de sus capacidade

Pautas WCAG: métodos y herramientas en el análisis y desarrollo de sitios web

Se resume los logros en la aplicación de métodos y herramientas destinadas a medir las pautas de accesibilidad de los contenidos web (WCAG 1.0 y 2.0) de diversos sitios, enfatizando en aquellos pertenecientes a organizaciones del NE y orientados a diversos dominios del conocimiento. Se consolida la formación de recursos humanos en la temática, incorporando los estudios realizados en el desarrollo de becas otorgadas por la UNNE y tesinas de grado.Eje: Ingeniería de SoftwareRed de Universidades con Carreras en Informática (RedUNCI

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Superparamagnetic iron oxide nanoparticles can providemultiple benefits for biomedical applications in aqueous environments such asmagnetic separation or magnetic resonance imaging. To increase the colloidal stability and allow subsequent reactions, the introduction of hydrophilic functional groups onto the particles’ surface is essential. During this process, the original coating is exchanged by preferably covalently bonded ligands such as trialkoxysilanes. The duration of the silane exchange reaction, which commonly takes more than 24 h, is an important drawback for this approach. In this paper, we present a novel method, which introduces ultrasonication as an energy source to dramatically accelerate this process, resulting in high-quality waterdispersible nanoparticles around 10 nmin size. To prove the generic character, different functional groups were introduced on the surface including polyethylene glycol chains, carboxylic acid, amine, and thiol groups. Their colloidal stability in various aqueous buffer solutions as well as human plasma and serum was investigated to allow implementation in biomedical and sensing applications.status: publishe

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Structure-Based Design of Scaffolds Targeting PDE10A by INPHARMA-NMR

Phosphodiesterases (PDE) hydrolyze both cyclic AMP and GMP (cAMP/cGMP) and are responsible for the regulation of their levels in a multitude of cellular functions. PDE10A is expressed in the brain and is a validated target for both schizophrenia and Huntington disease. Here, we address the identification of novel chemical scaffolds that may bind PDE10A via structure-based drug design. For this task, we use INPHARMA, an NMR-based method that measures protein-mediated interligand NOEs between pairs of weakly, competitively binding ligands. INPHARMA is applied to a combination of four chemically diverse PDE10A binding fragments, with the aim of merging their pharmacophoric features into a larger, tighter binding molecule. All four ligands bind the PDE10A cAMP binding domain with affinity in the micromolar range. The application of INPHARMA to identify the correct docking poses of these ligands is challenging due to the nature of the binding pocket and the high content of water-mediated intermolecular contacts. Nevertheless, ensemble docking in the presence of conserved water molecules generates docking poses that are in agreement with all sets of INPHARMA data. These poses are used to build a pharmacophore model with which we search the ZINC database